Response: Comorbidity of Epilepsy

Athanasios Gaitatzis,J. W. A. S. Sander
DOI: https://doi.org/10.1111/j.1528-1167.2005.18505_5.x
IF: 6.74
2005-01-01
Epilepsia
Abstract:To the Editor: We are grateful to Neville and Gillberg for pointing out the semantic problems in using the word “comorbidity” in the context of a heterogeneous condition like epilepsy, and we would like to comment. In our understanding, comorbidity in epilepsy refers to associated conditions and not to symptoms, medication side effects, or specific pathologies, such as hemiplegia, dizziness, or hippocampal sclerosis. In this respect, brain dysfunction associated with a syndromic diagnosis (e.g., Landau–Kleffner and West syndrome) would not count as comorbid, as it is usually part and parcel of the same condition. Strictly speaking, comorbidity in epilepsy should refer only to conditions that are not known causal factors for epilepsy. They may or may not share a common mechanism predisposing to the development of both disorders. It is not, however, always possible to differentiate between cause and effect in epidemiologic studies (1,2). Neville and Gillberg close by saying, Comorbidity may be a useful term in the epidemiology of epilepsy, in helping to define the support services required and raising research questions and hypotheses about why—for example—there is overall a high rate of autism spectrum disorder in a range of early onset epilepsies and why psychoses are overrepresented, as is illustrated in the study in question. This in an important statement and further emphasizes the importance of the study of the comorbidity of epilepsy.
What problem does this paper attempt to address?